Dr Uwe Wollina Named New Editor-in-Chief of Psoriasis: Targets and Therapy
Dr. Uwe Wollina has been named Editor-in-Chief of Dove Medical Press journal entitled Psoriasis: Targets and Therapy.
Dr. Wollina added: “During the last decade a never expected and still growing interst in psoriasis and psoriatic arthritis has been noted. The development has been driven by basic reasearch in inflammation and the availability of a completely new class of drugs - the biologicals.”
Head of the Department of Dermatology and Allergology at the Academic Teaching Hospital Dresden-Friedrichstadt and lecturer at the Friedrich-Schiller-University of Jena, Germany, Dr. Wollina has investigated abnormal epidermal differentiation in psoriasis vulgaris with a focus on calmodulin and lectin expression. His research had been related to lectins and lectin binding receptors in skin diseases, epidermal growth factor receptor expression in skin cancer, and clinical research in various fields of dermatology including noninvasive investigations in psoriasis and treatment. His current interest lies in clinical research and interdisciplinary approaches to improve medical care.
Dr. Wollina is director of International Society of Dermatology, President of European Society of Cosmetic and Aesthetic Dermatology, and member of the Scientific of Board of the German Psoriasis Foundation (DPB e.V.). At the national and international level he has served as a member of several editorial boards of multiple medical journals.
Psoriasis: Targets and Therapy is an international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life.
Dove Medical Press is a privately held publisher of 100+ open access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove was founded in 2003 and has offices in the United Kingdom and New Zealand, with an active presence in the USA and a network of agents in Europe, the Americas, and Southeast Asia.
Updated 23 July 2014